Metastatic castration-resistant prostate is an advanced form of the cancer that’s incurable. Learn about treatment options ...

Medically reviewed by Matthew Wosnitzer, MD Castration-resistant prostate cancer (CRPC) is a type of advanced prostate cancer ...

A panelist discusses how National Comprehensive Cancer Network (NCCN) guidelines have influenced molecular testing in ovarian cancer, highlighting the importance of biomarkers like BRCA genes for ...

Data shows Norway, which is similar in population size to NZ, increased its five-year survival rates for ovarian cancer from 34.1% to 46.1% in the almost two decades from 1995. In contrast, New ...

In a live virtual event, Thomas C. Krivak, MD, reviewed the key studies of PARP inhibitor and bevacizumab maintenance in ...

Olaparib, an inhibitor of poly (ADP-ribose) polymerase (PARP), has demonstrated promising outcomes in treating HER2-negative early-stage breast cancer with BRCA mutations. However, a comprehensive ...

Shuttle Pharmaceuticals (SHPH) announced the filing of a provisional patent application with the United States Patent and Trademark Office ...

The sector has seen billions in merger and acquisition activity in recent years; a September 2024 analysis by Insight ...

Combination treatment with a PARP inhibitor and an anti-angiogenic agent did not improve PFS when compared to chemotherapy or a PARP inhibitor alone.

Impact Therapeutics Inc. has synthesized poly(ADP-ribose) polymerase 1 (PARP-1; ARTD1) inhibitors reported to be useful for the treatment of neurologic cancer.

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They ...

Guidelines created by a multi-disciplinary panel of specialists focus on implementation of novel treatments and technologies for which level 1 evidence is lacking.